Trial · NCT07894120
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Main effectiveness indicators | 90 days after treatment | Overall clinical efficacy rate，Using the Fitzpatrick Skin Wrinkle and Elasticity Rating Scale, a four level evaluation was conducted on the improvement rate of wrinkles before and after treatment, based on the pre-treatment baseline: significant improvement, moderate improvement, mild improvement, and no improvement. ① Significant improvement: Wrinkle improvement rate\>75%; ② Moderate improvement: The wrinkle improvement rate is between 51% and 75%; ③ Mild improvement: The wrinkle improvement rate is between 25% and 50%; ④ No improvement: Wrinkle improvement rate\<25%. Overall clinical efficacy rate=(number of significantly improved cases+number of moderately improved cases+number of mildly improved cases)/total cases. |
| Primary | Main safety indicators | Before and immediately after treatment | Measure the respiratory frequency of the subject using a pulmonary function meter，in beats per minute |
| Primary | Main safety indicators | Before intervention, during treatment, and 90 days after treatment | Adverse event incidence rate |
| Primary | Secondary effectiveness indicators | On the 7th, 30th, and 90th day after treatment | VISIA Facial Rating |
| Primary | Secondary effectiveness indicators | Immediately after treatment | Visual Analogue Scale |
| Primary | Secondary effectiveness indicators | Immediately after treatment, 7 days after treatment | Skin reaction score |
| Primary | Secondary effectiveness indicators | 90 days after treatment | Using a satisfaction rating scale，Calculate the proportion of satisfied patients |
| Primary | Main safety indicators | Before and immediately after treatment | Using a thermometer to measure the patient's body temperature，Body temperature unit Celsius |
| Primary | Main safety indicators | Before and immediately after treatment | Measure the subject's pulse using a pulse oximeter, in beats per minute |
| Primary | Main safety indicators | Before and immediately after treatment | Measure the subject's blood pressure using a sphygmomanometer, in mmHg |
| Other | Secondary safety indicators | Immediately after treatment | Equipment failure rate |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07894120/registered